Skip to main content

Advertisement

Table 1 The demographic and clinical data

From: A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients

Parameters Fingolimod-treatment group IFNβ-treatment group
Age (mean ± SD) 39.08 ± 7.63 36.83 ± 7.24
Sex ratio (Female/male) 24/6 18/7
Disease duration 8.20 ± 3.42 8.77 ± 2.5
EDSS (mean ± SD) 4.92 ± 0.73 4.52 ± 1.09